What is HC Wainwright’s Estimate for BBIO Q2 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for BridgeBio Pharma in a research report issued on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.77) for the quarter. HC Wainwright currently has a “Buy” rating and a $53.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.98) EPS.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million.

A number of other research analysts have also issued reports on BBIO. Cantor Fitzgerald restated an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Citigroup raised their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. increased their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 24th. Finally, Evercore ISI boosted their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO opened at $33.85 on Wednesday. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $39.47. The firm’s 50-day simple moving average is $33.69 and its 200 day simple moving average is $29.95. The firm has a market cap of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of BBIO. Ironwood Investment Management LLC grew its stake in BridgeBio Pharma by 0.5% in the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company’s stock valued at $1,733,000 after acquiring an additional 338 shares during the period. GAMMA Investing LLC lifted its stake in shares of BridgeBio Pharma by 71.0% in the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock valued at $32,000 after buying an additional 382 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of BridgeBio Pharma by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company’s stock valued at $404,000 after buying an additional 466 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after acquiring an additional 472 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of BridgeBio Pharma by 6.6% in the 4th quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock worth $261,000 after acquiring an additional 592 shares during the last quarter. 99.85% of the stock is owned by institutional investors.

Insider Activity

In other news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the completion of the sale, the insider now directly owns 19,260,971 shares in the company, valued at $634,841,604.16. This represents a 23.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Neil Kumar sold 326,932 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28. Following the sale, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at approximately $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,694,739 shares of company stock worth $327,308,651. Corporate insiders own 24.66% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.